Navamedic ASA (NAVA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Navamedic ASA (NAVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10151
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ノルウェー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Navamedic ASA (Navamedic) is a medtech and pharmaceutical products company, which develops, distributes and markets medicines and medical equipment. Its product portfolio includes branded, generic and patented pharmaceuticals, medical devices, food supplements and other healthcare products. The company offers its products to patients, hospitals and pharmacies in the Nordic, Benelux and Baltic markets. Navamedic offers its pharmaceutical products under mouth and throat health, dermatology, urology, gynecology, cardiology and other categories; and medical devices under urine measurement and psychiatry categories. The company also distributes products supplied by several pharmaceutical manufacturers. Navamedic is headquartered in Lysaker, Norway.

Navamedic ASA (NAVA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Navamedic ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Navamedic ASA, Medical Devices Deals, 2012 to YTD 2018 9
Navamedic ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Navamedic ASA, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Navamedic Enters into Agreement with G. Pohl-Boskamp 11
Navamedic Enters into Agreement with bene-Arzneimittel 12
Orexigen Therapeutics Enters into Distribution Agreement with Navamedic 13
Navamedic Plans to Enter into Commercialization Agreement with TopRidge Pharma for Sippi 14
Navamedic Expands Distribution Agreement with TopRidge Pharma for Imdur 15
Biotec Pharmacon Enters into Distribution Agreeement with Navamedic 16
Navamedic Enters Into Distribution Agreement With Torrent Pharma 17
Navamedic Amends Distribution Agreement With Aspen Pharma 18
Equity Offering 19
Navamedic Raises USD1.3 Million in Private Placement of Shares 19
Navamedic ASA – Key Competitors 20
Navamedic ASA – Key Employees 21
Navamedic ASA – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Aug 24, 2018: Navamedic: Q2 2018 results 23
May 30, 2018: Navamedic Announces Q1 2018 results 24
Feb 15, 2018: Navamedic: Q4 2017 Results 25
Nov 10, 2017: Navamedic: Q3 2017 results 26
Jul 28, 2017: Navamedic ASA: Second quarter results 2017 27
Jul 28, 2017: Navamedic: Second quarter results 2017 28
May 10, 2017: Navamedic: Q1 2017 Results 29
Feb 15, 2017: Navamedic: Q4 2016 results 30
Corporate Communications 31
Oct 01, 2018: Navamedic announce Tom Ronnlund to step down as CEO 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
Navamedic ASA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Navamedic ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Navamedic ASA, Deals By Therapy Area, 2012 to YTD 2018 8
Navamedic ASA, Medical Devices Deals, 2012 to YTD 2018 9
Navamedic ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Navamedic Enters into Agreement with G. Pohl-Boskamp 11
Navamedic Enters into Agreement with bene-Arzneimittel 12
Orexigen Therapeutics Enters into Distribution Agreement with Navamedic 13
Navamedic Plans to Enter into Commercialization Agreement with TopRidge Pharma for Sippi 14
Navamedic Expands Distribution Agreement with TopRidge Pharma for Imdur 15
Biotec Pharmacon Enters into Distribution Agreeement with Navamedic 16
Navamedic Enters Into Distribution Agreement With Torrent Pharma 17
Navamedic Amends Distribution Agreement With Aspen Pharma 18
Navamedic Raises USD1.3 Million in Private Placement of Shares 19
Navamedic ASA, Key Competitors 20
Navamedic ASA, Key Employees 21
Navamedic ASA, Subsidiaries 22

List of Figures
Navamedic ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Navamedic ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Navamedic ASA, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Navamedic ASA (NAVA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM)-製薬・医療分野:企業M&A・提携分析
    Summary J B Chemicals and Pharmaceuticals Ltd (JBCPL) is a pharmaceutical company that provides contract manufacturing services. The company manufacturers tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups and capsules. Its services include optimization of formulations, sc …
  • Holder Construction Co:企業の戦略的SWOT分析
    Holder Construction Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Strand Life Sciences Pvt Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Strand Life Sciences Pvt Ltd (Strand Life) is a healthcare technology company that develops offers bioinformatics and clinical diagnostic software products. The company offers bioinformatics software for most analytics platforms such as microarrays, mass spectrometry, next generation sequenc …
  • The Home Depot, Inc.:企業の戦略・SWOT・財務情報
    The Home Depot, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Home Depot, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Glory Ltd:企業の戦略・SWOT・財務分析
    Glory Ltd - Strategy, SWOT and Corporate Finance Report Summary Glory Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Xencor Inc (XNCR):企業の財務・戦略的SWOT分析
    Summary Xencor Inc (Xencor) is a clinical-stage biopharmaceutical company that develops engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. The company provides pipeline products under preclinical development such as XmAb14045, for the …
  • Tesaro Inc (TSRO)-医療機器分野:企業M&A・提携分析
    Summary Tesaro Inc (Tesaro) is an oncology-focused biopharmaceutical company that focuses on developing in-licensed, oncology-related product candidates, comprising rolapitant, niraparib, and the product candidates under its immuno-oncology platform. VARUBI, the company’s first commercial product is …
  • One Way Liver SL-製薬・医療分野:企業M&A・提携分析
    Summary One Way Liver SL (OWL), formerly One Way Liver Genomics SL is a biotechnology company that discovers, develops and offers diagnostic products and metabolomics services for the healthcare sector. The company commercializes OWLiver, which is a serum based test used for steatosis and NASH diagn …
  • Severoceske doly as:企業の戦略・SWOT・財務情報
    Severoceske doly as - Strategy, SWOT and Corporate Finance Report Summary Severoceske doly as - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Indianapolis Power & Light Co:企業の発電所・SWOT分析2018
    Indianapolis Power & Light Co - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Taiwan Shin Kong Commercial Bank Co., Ltd.:企業の戦略・SWOT・財務情報
    Taiwan Shin Kong Commercial Bank Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Taiwan Shin Kong Commercial Bank Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Isagenix International LLC:企業の戦略的SWOT分析
    Isagenix International LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Soil Machine Dynamics Ltd:企業の戦略的SWOT分析
    Soil Machine Dynamics Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Bri-Chem Corp (BRY):石油・ガス:M&Aディール及び事業提携情報
    Summary Bri-Chem Corp (Bri-Chem) is an oil and gas drilling fluids provider. It manufactures, blends, packs and conducts wholesale distribution of oilfield drilling, completion, stimulation and production chemical fluids. The company supplies custom blended cementing, acidizing and fracturing chemic …
  • LyondellBasell Industries NV (LYB)-石油・ガス分野:企業M&A・提携分析
    Summary LyondellBasell Industries N.V. (LyondellBasell) is a chemical company. It produces and sells petrochemicals, plastics and basic chemicals. The company also refines crude oil to convert into refined products such as gasoline, diesel and jet fuel. Its major chemical products include polyolefin …
  • CITIC Securities Company Limited:戦略・SWOT・企業財務分析
    CITIC Securities Company Limited - Strategy, SWOT and Corporate Finance Report Summary CITIC Securities Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Citius Pharmaceuticals Inc (CTXR)-製薬・医療分野:企業M&A・提携分析
    Summary Citius Pharmaceuticals Inc (Citius), formerly Trail One Inc, is a specialty pharmaceutical company that focused on the development and commercialization of adjunctive cancer care and critical care drug products. The company‘s proprietary product candidates include mino-lok, an antibiotic loc …
  • Senior Lifestyle Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Senior Lifestyle Corp (Senior Lifestyle) is a healthcare service provider that provides healthcare and resident services. The company owns and operates several senior living apartments and retirement communities. It provides life enrichment programs such as cultural and social activities, tr …
  • CME Group Inc.:戦略・SWOT・企業財務分析
    CME Group Inc. - Strategy, SWOT and Corporate Finance Report Summary CME Group Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Dyadic International Inc (DYAI):企業の財務・戦略的SWOT分析
    Summary Dyadic International Inc (Dyadic) is a biotechnology company that develops, discovers, manufactures, and commercializes protein-based drugs. The company utilizes its patented and proprietary technology Myceliopthora thermophila expression systems to conduct research and produce industrial en …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆